Advertisement

Nonalcoholic Fatty Liver Disease Treatment

  • Marko Duvnjak
  • Dominik Kralj
Chapter
Part of the Clinical Gastroenterology book series (CG)

Abstract

Patients with nonalcoholic fatty liver disease and concomitant type 2 diabetes mellitus are at an increased risk of disease progression, leading to cirrhosis and hepatocellular carcinoma. Lifestyle interventions leading to weight loss, including a Mediterranean diet and increased physical activity, are key to improving outcomes in this group of patients. A pharmacological therapeutic approach that could reduce liver steatosis, inflammation, and consequent fibrosis is still not defined. Pioglitazone, an insulin sensitizer, can be considered in these patients for achieving adequate glycemic control, as current evidence suggests a benefit in terms of histological improvement. Many candidate pharmacological agents, including other insulin sensitizers, lipid-lowering drugs, and antioxidants, are currently being tested to treat NAFLD. Targeting anti-inflammatory, anti-fibrotic, and anti-apoptotic pathways as well as bile acid metabolism and gut microbiota is also under investigation. Better quality evidence for treating NAFLD, especially in type 2 diabetes patients, is needed and should be available in the foreseeable future.

Keywords

Nonalcoholic fatty liver disease Therapy Lifestyle modification Weight loss Mediterranean diet Insulin sensitizers Anti-oxidants Obeticholic acid Anti-fibrotics 

References

  1. 1.
    Salas-Salvadó J, Guasch-Ferré M, Lee CH, et al. Protective effects of the Mediterranean diet on type 2 diabetes and metabolic syndrome. J Nutr. 2016;146(4):920S–7S.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.e5.CrossRefPubMedGoogle Scholar
  3. 3.
    Billeter AT, Senft J, Gotthardt D, et al. Combined non-alcoholic fatty liver disease and type 2 diabetes mellitus: sleeve gastrectomy or gastric bypass?—a controlled matched pair study of 34 patients. Obes Surg. 2016;26(8):1867–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Bacchi E, Negri C, Targher G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial). Hepatology. 2013;58(4):1287–95.CrossRefPubMedGoogle Scholar
  5. 5.
    Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305–15.CrossRefPubMedGoogle Scholar
  6. 6.
    Cernea S, Cahn A, Raz I. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Rev Clin Pharmacol. 2017;10(5):535–47.  https://doi.org/10.1080/17512433.2017.1300059.CrossRefPubMedGoogle Scholar
  7. 7.
    Pastori D, Polimeni L, Baratta F, et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47(1):4–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Gross B, Pawlak M, Lefebvre P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol. 2017;13(1):36–49.CrossRefPubMedGoogle Scholar
  9. 9.
    Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zeng T, Zhang CL, Zhao XL, Xie KQ. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. Eur J Gastroenterol Hepatol. 2014;26(6):646–53.  https://doi.org/10.1097/MEG.0000000000000068.CrossRefPubMedGoogle Scholar
  11. 11.
    Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180–90.  https://doi.org/10.1136/gutjnl-2016-312431. Published Online First: 19 Sept 2016.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Marko Duvnjak
    • 1
    • 2
  • Dominik Kralj
    • 1
  1. 1.Department of Gastroenterology and HepatologySestre Milosrdnice University Hospital CenterZagrebCroatia
  2. 2.University of Zagreb School of MedicineZagrebCroatia

Personalised recommendations